en · de · es · fr · pt
selank-notes.peptides6608.com › Topic › Selank Background And Chemical Identity — Field Notes

Selank Background And Chemical Identity — Field Notes

By Editorial Desk · published 2025-11-15 · last reviewed 2025-12-23 · Topic

Research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2025-12-23. Where a claim depends on a specific study, the study is described rather than over-claimed.

Selank Background And Chemical Identity

Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.

The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.

Analytical Methods and Stability

Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.

Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.

Selank at a glance

PropertyValueNotes
Molecular classSynthetic heptapeptideStabilized analog of tuftsin
SequenceThr-Lys-Pro-Arg-Pro-Gly-ProSingle-letter form: TKPRPGP
Molecular formulaC33H57N11O9Monoisotopic mass about 751.9 Da
AppearanceWhite to off-white powderTypically supplied as lyophilized solid
SolubilityFreely soluble in waterAlso soluble in common polar solvents

Storage, Analysis, and Regulatory Status

Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.

Related pages on this site

Selank Origin and Chemical Identity

Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.

Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.

The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.

Further detail

== Applications == The simplicity and efficiency of MEKC have made it an attractive technique for a variety of applications. Further improvements can be made to the selectivity of MEKC by adding chiral selectors or chiral surfactants to the system. Unfortunately, this technique is not suitable for protein analysis because proteins are generally too large to partition into a surfactant micelle and tend to bind to surfactant monomers to form SDS-protein complexes. Recent applications of MEKC include the analysis of uncharged pesticides, essential and branched-chain amino acids in nutraceutical products, hydrocarbon and alcohol contents of the marjoram herb. MEKC has also been targeted for its potential to be used in combinatorial chemical analysis. The advent of combinatorial chemistry has enabled medicinal chemists to synthesize and identify large numbers of potential drugs in relatively short periods of time. Small sample and solvent requirements and the high resolving power of MEKC have enabled this technique to be used to quickly analyze a large number of compounds with good resolution. Traditional methods of analysis, like high-performance liquid chromatography (HPLC), can be used to identify the purity of a combinatorial library, but assays need to be rapid with good resolution for all components to provide useful information for the chemist. The introduction of surfactant to traditional capillary electrophoresis instrumentation has dramatically expanded the scope of analytes that can be separated by capillary electrophoresis.

Dominant genes associated with PD but now believed unlikely to be pathogenic include HTRA2, UCHL1 (PARK5), GIGYF2 (PARK11), and EIF4G1. Autosomal recessive genes include PRKN (PARK2, PARKIN), PINK1 (PARK6), PARK7 (DJ-1), ATP13A2 (PARK9), PLA2G6 (PARK14, IPLA2), FBXO7 (PARK15, FBX7), DNAJC6 (PARK19, DJC6), SYNJ1 (PARK20), and VPS13C (PARK23). Most common risk genes (like GBA) affect both sexes equally. The overall genetic risk for PD appears to be similar for males and females. However, there are sex- and gender-related differences between men and women in PD clinical features, disease development and response to treatment. Men are consistently found to have a higher occurrence of Parkinson's disease, with an estimated prevalence rate 1.5 times greater among males than females across all ages. These differences appear to reflect complex interactions among hormones, gene regulation, and other biological, environmental and sociocultural factors. Some sex-linked factors may differently affect brain activity and dopamine pathways. In adult males, the SRY gene (Sex-determining Region on the Y chromosome) is involved in regulation of dopamine, and SRY overactivity may increase PD risk. In women, hormones such as estrogen have been suggested to have a protective effect against PD, but little research has been done.

=== Pharmacotherapy === Sodium thiosulfate is commonly prescribed for treatment in patients with calciphylaxis. The actual mechanism of the drug is unknown, but several explanations have been proposed, including chelation of calcium, vasodilation, antioxidant properties, and restoration of endothelial function. Adverse effects of sodium thiosulfate include high anion gap metabolic acidosis and high sodium levels (hypernatremia). Bisphosphonates are a popular choice for the treatment of osteoporosis, but they have also been used to treat calciphylaxis even though the exact mechanism in calciphylaxis is unknown. They are most beneficial in patients who have a genetic ENPP1 deficiency and have been shown to slow development of calciphylaxis lesions in a small prospective study. Cinacalcet (medication parathyroidectomy) is an oral medication that can be used to suppress the parathyroid glands for patients who may not be able to undergo surgical parathyroidectomy. Vitamin K supplementation has also been shown to slow development of calcification in coronary arteries and the aortic valve in older patients. The ability of vitamin K supplementation to slow calcification of blood vessels in calciphylaxis is not well-studied. Warfarin, a vitamin K antagonist discussed above, should be discontinued if possible. Other acceptable treatments may include one or more of the following:

Sources: en.wikipedia.org

Background from the literature

=== Miscellaneous === Liquids are sometimes used in measuring devices. A thermometer often uses the thermal expansion of liquids, such as mercury, combined with their ability to flow to indicate temperature. A manometer uses the weight of the liquid to indicate air pressure. The free surface of a rotating liquid forms a circular paraboloid and can therefore be used as a telescope. These are known as liquid-mirror telescopes. They are significantly cheaper than conventional telescopes, but can only point straight upward (zenith telescope). A common choice for the liquid is mercury.

All serpins share a common structure (or fold), despite their varied functions. All typically have three β-sheets (named A, B and C) and eight or nine α-helices (named hA–hI). The most significant regions to serpin function are the A-sheet and the reactive centre loop (RCL). The A-sheet includes two β-strands that are in a parallel orientation with a region between them called the 'shutter', and upper region called the 'breach'. The RCL forms the initial interaction with the target protease in inhibitory molecules. Structures have been solved showing the RCL either fully exposed or partially inserted into the A-sheet, and serpins are thought to be in dynamic equilibrium between these two states. The RCL also only makes temporary interactions with the rest of the structure, and is therefore highly flexible and exposed to the solvent. The serpin structures that have been determined cover several different conformations, which has been necessary for the understanding of their multiple-step mechanism of action. Structural biology has therefore played a central role in the understanding of serpin function and biology.

However, although (R)-MDMA partially substitutes for lysergic acid diethylamide (LSD) in animal drug discrimination tests, it did not produce the head-twitch response, a behavioral proxy of psychedelic effects, at any tested dose. In any case, findings in this area are conflicting. (R)-MDMA is inactive as an agonist of the human TAAR1, whereas (S)-MDMA shows very weak potency as an agonist of the receptor (EC50Tooltip half-maximal effective concentration = 74,000 nM). MDMA is a well-known serotonergic neurotoxin and this has been demonstrated both in animals and in humans. There is evidence that the serotonergic neurotoxicity of MDMA may be driven primarily by (S)-MDMA rather than (R)-MDMA. (R)-MDMA shows substantially lower or potentially no neurotoxicity compared to (S)-MDMA in animal studies. This has been the case even when doses of (R)-MDMA were increased to account for its lower potency than (S)-MDMA. However, more research is needed to confirm this in other species, such as non-human primates. In contrast to (S)-MDMA, (R)-MDMA does not produce hyperthermia in rodents, and this may be involved in its reduced risk of neurotoxicity, as hyperthermia augments and is essential for the serotonergic neurotoxicity of MDMA. The reduced potency of (R)-MDMA as a dopamine releasing agent may also be involved in its reduced neurotoxic potential, as dopamine release is likewise essential for the neurotoxicity of MDMA. The hyperthermia of MDMA may in fact be mediated by dopamine release.

The BOP was aware that the use of pentobarbital as their "new drug choice" would be challenged in the courts because some lawyers had said that "pentobarbital would flood prisoners' lungs with froth and foam, inflicting pain and terror akin to a death by drowning." BOP claimed that these concerns were unjustified and that their two expert witnesses asserted that the use of pentobarbital was "humane". On 25 July 2019, US Attorney General William Barr directed the federal government to resume capital punishment after 16 years, despite shortages of the compound caused by European Union restrictions and a lack of U.S. manufacturers. The federal protocol provides for intravenous administration of two syringes each containing 2.5 grams of pentobarbital sodium followed by a saline flush.

Sources: en.wikipedia.org

Further detail

6 May 1986 – USS Ray, USS Archerfish and USS Hawkbill meet and surface together at the Geographic North Pole. First three-submarine surfacing at the Pole. 19 May 1987 – HMS Superb joined USS Billfish and USS Sea Devil at the North Pole. March 2007 – USS Alexandria participated in the Joint US Navy/Royal Navy Ice Exercise 2007 (ICEX-2007) in the Arctic Ocean with the Trafalgar-class submarine HMS Tireless. March 2009 – USS Annapolis took part in Ice Exercise 2009 to test submarine operability and war-fighting capability in Arctic conditions.

In 1917–18, two groups of scientists, Lise Meitner in collaboration with Otto Hahn of Germany and Frederick Soddy and John Cranston of Great Britain, independently discovered another isotope, 231Pa, having a much longer half-life of 32,760 years. Meitner changed the name "brevium" to protactinium as the new element was part of the decay chain of uranium-235 as the parent of actinium (from the Greek: πρῶτος prôtos, meaning "first, before"). The IUPAC confirmed this naming in 1949. The discovery of protactinium completed one of the last gaps in early versions of the periodic table, and brought fame to the involved scientists. Aristid von Grosse produced 2 milligrams of Pa2O5 in 1927, and in 1934 first isolated elemental protactinium from 0.1 milligrams of Pa2O5. He used two different procedures: in the first, protactinium oxide was irradiated by 35 keV electrons in vacuum. In the other, called the van Arkel–de Boer process, the oxide was chemically converted to a halide (chloride, bromide or iodide) and then reduced in a vacuum with an electrically heated metallic filament:

=== Angiogenesis === The formation of new blood vessels is essential for tumor survival and expansion. Intracrines like VEGF and angiogenin regulate angiogenesis within tumor cells and surrounding endothelial cells. Inhibiting intracrine trafficking of angiogenin to the nucleus has been shown to blunt cancer cell proliferation, making this an emerging therapeutic target.

==== Cannabinoids ==== According to a study published in the August 15, 2004 issue of the journal Cancer Research, cannabinoids, the active ingredients in marijuana, restrict the sprouting of blood vessels to gliomas (brain tumors) implanted under the skin of mice, by inhibiting the expression of genes needed for the production of vascular endothelial growth factor (VEGF).

=== Diagnosis and treatment === In current practice for dogs, B. canis is diagnosed using PCR, cultures, and serologic testing. The most standard test for B. canis is culture. These cultures are typically conducted on the host's blood, vaginal discharge, or semen. However, this method is not effective if the dog has been treated with antimicrobial drugs, as this will clear B. canis bacteria even if the disease has not resolved. Serology is used to evaluate the antibody response against Brucella spp. cell wall antigens, the downfall of this method is its lack of specificity. PCR testing has shown potential as a rapid test, however it is not readily available and is currently considered an experimental test. Currently, there are not commercially available vaccines for B. canis. Antimicrobial treatment and sterilization of the infected animals is considered an alternative to removing the animal. There have been reports of anti-Brucella vaccines (used for cattle and small ruminants), used along with previously mentioned methods but is not considered practical due to its risk of vaccine strain shedding in a domestic environment with current vaccines maintaining an amount of virulence for humans. Treatment for B. canis is very difficult to find and often very expensive. This is due to B. canis being a intracellular bacteria, meaning it replicates inside of host cells rather than outside of them. This makes it difficult for antibiotics to reach the bacteria.

Sources: en.wikipedia.org

Frequently asked questions

What is Selank?

Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.

Where was Selank developed?

It was developed in Russia, at the Institute of Molecular Genetics of the Russian Academy of Sciences, during the 1990s. Most published research originates from Russian institutions. Independent international replication remains limited.

How does Selank differ from tuftsin?

Tuftsin is a natural tetrapeptide with the sequence Thr-Lys-Pro-Arg that participates in immune signaling. Selank extends that sequence with Pro-Gly-Pro at the C-terminus. The added residues are linked to greater resistance to enzymatic breakdown.

How is selank identified in a laboratory?

Identity is confirmed by matching the retention time in reversed-phase chromatography against a reference standard and by measuring the molecular mass with mass spectrometry. Tandem mass spectrometry or amino acid analysis can verify the sequence of the seven residues. Because the peptide contains no aromatic amino acids, detection at 280 nm is not useful.

Network